Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Novel histocompatibility loci in man

Project description

Uncovering hidden human histocompatibility loci

The immune system has the ability to distinguish between self and non-self. Regulation of immune responses are mediated by proteins encoded by highly polymorphic histocompatibility loci located within the major histocompatibility complex (MHC), also known as human leukocyte antigen (HLA) in man. Although matching of HLA molecules reduces complications in bone marrow transplantation and graft rejection, it does not eliminate them. The ERC-funded Histogenomics project aims to identify all unknown histocompatibility loci present in the human genome. Using a pluri-omics approach on kidney transplants and haematopoietic cell transplants, candidate loci will be validated for their ability to elicit immune responses. This unbiased, data-driven method aims to enhance understanding of graft versus host disease and rejection, leading to personalised transplant therapies.

Objective

Allogeneic tissue graft (hematopoietic cell transplantation; HCT) and solid organ transplantation (SOT) (Kidney, Heart, Lung,..) save tens of thousands of lives annually. Yet their success is compounded by a high incidence of the potentially fatal graft-versus-host disease (GvHD) in HCT and chronic rejection (CR) in SOT. This is primarily due to the existence of yet unknown histocompatibility loci which have escaped detection - besides certain immunogenic peptides - since the identification of the Major Histocompatibility Complex (MHC; also called Human Leukocyte antigen HLA in man) in 1940-1950s. The identification of these hitherto unknown histocompatibility loci in man is the major aim of this proposal. Our contribution to MHC genetics includes the identification of the sole, non-HLA, MHC-encoded, class I molecules; the MHC class I chain-related MIC genes (A second lineage of mammalian major histocompatibility complex class I genes. | PNAS), which we recently qualified as a bona fide histocompatibility gene (The MHC class I MICA gene is a histocompatibility antigen in kidney transplantation | Nature Medicine). Here we aim to identify the totality of histocompatibility loci embedded within our genome. We will apply a pluri-omics approach (successfully applied elsewhere Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort (science.org)) on deeply phenotyped cohorts of kidney transplants and HCT. Identified candidate loci will be validated based on their ability to be presented by MHC molecule and to elicit T- and/or B-cell responses. In contrast to the classical, hypothesis-driven approaches, which have collectively failed to identify universally applicable such loci in the past 70 years, our approach is unbiased, data-driven and unprecedented in the field. It shall have direct relevance in our understanding of the primum movens of GvHD and CR and shall lead to a personalized therapy of the transplant patient.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2023-ADG

See all projects funded under this call

Host institution

UNIVERSITE DE STRASBOURG
Net EU contribution
€ 2 500 000,00
Address
RUE BLAISE PASCAL 4
67081 Strasbourg
France
Region
Grand Est Alsace Bas-Rhin
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 2 500 000,00

Beneficiaries (1)